Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative chemoradiation with cisplatin + irinotecan versus carboplatin + paclitaxel in esophageal cancer
IRCT20141102019783N5Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Jun 2015
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of cisplatin, irinotecan, carboplatin and paclitaxel in esophageal cancer (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoint: Survival rate. Started Jun 2015; status: completed.
02
Drugs
cisplatinirinotecancarboplatinpaclitaxel
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on IRCT20141102019783N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20141102019783N5.